Bruker (BRKR)
(Delayed Data from NSDQ)
$64.54 USD
+0.81 (1.27%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $64.54 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
C Value D Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$64.54 USD
+0.81 (1.27%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $64.54 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
C Value D Growth A Momentum C VGM
Zacks News
Microchip (MCHP) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Microchip's (MCHP) fiscal third-quarter results are likely to reflect robust uptake of microcontrollers, despite supply chain constraints and weak consumer end-market.
Cognizant (CTSH) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
Cognizant's (CTSH) fourth-quarter 2022 results are expected to reflect growing domain expertise in its digital business operations despite challenging macroeconomic conditions.
Bruker's (BRKR) New Tie-Up to Expand Its U.S. CRO Business
by Zacks Equity Research
Bruker's (BRKR) latest partnership is expected to expand its CRO business in the United States, benefiting more biopharma and diagnostics companies using unbiased proteomics for decision-making.
Are Options Traders Betting on a Big Move in Bruker (BRKR) Stock?
by Zacks Equity Research
Investors need to pay close attention to Bruker (BRKR) stock based on the movements in the options market lately.
Bruker (BRKR) Q3 Earnings Beat Estimates, '22 Sales View Down
by Zacks Equity Research
Despite ongoing macroeconomic headwinds, Bruker (BRKR) registers strong demand for differentiated high-value scientific instruments and life science solutions.
Bruker (BRKR) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Bruker (BRKR) delivered earnings and revenue surprises of 24.53% and 4.14%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Bruker (BRKR) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Bruker (BRKR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BD's (BDX) New Cloud Software Solution to Boost Lab Workflow
by Zacks Equity Research
BD's (BDX) latest launch is expected to provide scientists with an integrated ecosystem that enables optimization of panel design, collaboration and analysis.
Bruker (BRKR) Gains From New Product Bookings Amid Competition
by Zacks Equity Research
Bruker's (BRKR) revenue recognition from one gigahertz class NMR system and continued uptake of the timsTOF platform hold promise.
Here's Why You Should Retain Bruker (BRKR) Stock for Now
by Zacks Equity Research
Investors are optimistic about Bruker's (BRKR) segmental results and robust bookings and backlog growth.
Why Is Bruker (BRKR) Down 11.3% Since Last Earnings Report?
by Zacks Equity Research
Bruker (BRKR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Bruker (BRKR) Debuts Innovations for Proteomics & Metabolomics
by Zacks Equity Research
Bruker's (BRKR) novel nanoElute 2 and next-generation MetaboScape 2023 release are likely to offer enhanced workflows for proteomics and metabolomics applications.
BD (BDX) Ties Up With LabCorp to Boost Patient Outcome
by Zacks Equity Research
BD's (BDX) latest partnership is expected to provide life-changing treatments for cancer and other diseases, thereby improving patient care.
Bruker (BRKR) Q2 Earnings Match Estimates, '22 Sales View Down
by Zacks Equity Research
Robust performance across the BSI and BEST segments drove Bruker's (BRKR) second-quarter top line.
Bruker (BRKR) Meets Q2 Earnings Estimates
by Zacks Equity Research
Bruker (BRKR) delivered earnings and revenue surprises of 0% and 0.43%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
MedTech Stocks to Watch for Earnings on Aug 3
by Zacks Equity Research
MedTech players are likely to have benefited from the consistent opening of economies and sales contributions from high testing demand. Let's see how CRL, CVS, BRKR and NUVA fare this time.
Waters (WAT) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Waters (WAT) delivered earnings and revenue surprises of 4.56% and 1.24%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
PerkinElmer (PKI) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
PerkinElmer (PKI) delivered earnings and revenue surprises of 14.29% and 2.25%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Bruker (BRKR) Earnings Expected to Grow: What to Know Ahead of Q2 Release
by Zacks Equity Research
Bruker (BRKR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bruker (BRKR) Debuts NMR Test for Research on Long COVID Risks
by Zacks Equity Research
Bruker's (BRKR) PhenoRisk PACS RuO will facilitate clinical research to combat the risks of Long COVID syndrome.
Bruker (BRKR) International Growth Strong Amid Competition
by Zacks Equity Research
Bruker (BRKR) Nano Group's microelectronics and semiconductor metrology tools continue to perform well with ongoing strength in bookings and backlog.
Zacks Industry Outlook Highlights Mettler-Toledo International, Waters and Bruker
by Zacks Equity Research
Mettler-Toledo International, Waters and Bruker have been highlighted in this Industry Outlook article.
3 Stocks to Watch on Rising Demand for Scientific Instruments
by Aniruddha Ganguly
The Zacks Instruments - Scientific industry participants like Mettler-Toledo (MTD), Waters (WAT) and Bruker (BRKR) are gaining from strong life science, pharmaceutical and academic end-market demand, as well as rising healthcare spending.
Bruker (BRKR) BSI & BEST Arms Drive Growth Amid Competition
by Zacks Equity Research
Bruker (BRKR) Nano Group's microelectronics and semiconductor metrology tools continue to perform well with ongoing strength in bookings and backlog.
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.